Cellumed Co.,Ltd. (KOSDAQ:049180)
1,491.00
-109.00 (-6.81%)
At close: Feb 5, 2026
Cellumed Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 148,549 | 129,140 | 95,553 | 122,085 | 99,918 | 73,188 |
Other Revenue | - | - | -0 | - | - | - |
| 148,549 | 129,140 | 95,553 | 122,085 | 99,918 | 73,188 | |
Revenue Growth (YoY) | 24.16% | 35.15% | -21.73% | 22.19% | 36.52% | 308.38% |
Cost of Revenue | 142,334 | 119,711 | 89,984 | 108,521 | 85,619 | 58,920 |
Gross Profit | 6,215 | 9,428 | 5,569 | 13,564 | 14,299 | 14,267 |
Selling, General & Admin | 11,039 | 12,209 | 12,672 | 14,051 | 10,898 | 9,708 |
Research & Development | 1,536 | 1,225 | 1,506 | 1,523 | 1,170 | 783.23 |
Amortization of Goodwill & Intangibles | 65.53 | 262.11 | 369.46 | 325.59 | 331.13 | 361.85 |
Other Operating Expenses | 154.9 | 160.92 | 159.4 | 217.39 | 264.22 | 174.44 |
Operating Expenses | 15,752 | 17,888 | 29,446 | 18,110 | 9,552 | 12,386 |
Operating Income | -9,537 | -8,459 | -23,878 | -4,546 | 4,747 | 1,881 |
Interest Expense | -919.42 | -1,344 | -1,673 | -2,496 | -1,510 | -440.68 |
Interest & Investment Income | 454.17 | 543.32 | 734.4 | 681.29 | 878.3 | 114.31 |
Earnings From Equity Investments | -550.16 | -1,481 | -1,333 | 3,600 | 3,426 | - |
Currency Exchange Gain (Loss) | -804.6 | -1,003 | -87.9 | 290.95 | -160.58 | 212.47 |
Other Non Operating Income (Expenses) | -6,140 | -14,202 | 704.63 | -1,520 | 1,316 | 298.63 |
EBT Excluding Unusual Items | -17,497 | -25,946 | -25,532 | -3,989 | 8,696 | 2,066 |
Gain (Loss) on Sale of Investments | 551.36 | -276.45 | 554.53 | 24.64 | 386.79 | -61.6 |
Gain (Loss) on Sale of Assets | -4.65 | -16.68 | 17.99 | 128.95 | -0.97 | 310.18 |
Asset Writedown | -4,724 | -4,724 | -13,621 | -965.28 | -6.3 | -793.04 |
Other Unusual Items | - | -1,122 | - | 0.67 | - | 12.13 |
Pretax Income | -21,674 | -32,085 | -38,581 | -4,800 | 9,076 | 1,534 |
Income Tax Expense | -241.73 | -267.33 | -654.13 | 383.68 | 816.51 | 915.99 |
Earnings From Continuing Operations | -21,432 | -31,817 | -37,927 | -5,184 | 8,259 | 617.52 |
Earnings From Discontinued Operations | - | - | -17.7 | -203.3 | 170.61 | 445.1 |
Net Income to Company | -21,432 | -31,817 | -37,945 | -5,387 | 8,430 | 1,063 |
Minority Interest in Earnings | 135.36 | 272.06 | 646.86 | -183.61 | -248.81 | -1,695 |
Net Income | -21,297 | -31,545 | -37,298 | -5,571 | 8,181 | -632.58 |
Net Income to Common | -21,297 | -31,545 | -37,298 | -5,571 | 8,181 | -632.58 |
Shares Outstanding (Basic) | 53 | 49 | 43 | 40 | 39 | 29 |
Shares Outstanding (Diluted) | 53 | 49 | 43 | 40 | 39 | 29 |
Shares Change (YoY) | 13.80% | 14.33% | 6.45% | 2.14% | 37.23% | 32.82% |
EPS (Basic) | -400.81 | -648.25 | -876.33 | -139.33 | 209.00 | -22.18 |
EPS (Diluted) | -400.81 | -648.25 | -876.33 | -139.33 | 209.00 | -22.18 |
Free Cash Flow | -4,661 | -2,202 | -9,535 | -10,092 | -4,941 | -4,174 |
Free Cash Flow Per Share | -87.72 | -45.26 | -224.04 | -252.39 | -126.23 | -146.32 |
Gross Margin | 4.18% | 7.30% | 5.83% | 11.11% | 14.31% | 19.49% |
Operating Margin | -6.42% | -6.55% | -24.99% | -3.72% | 4.75% | 2.57% |
Profit Margin | -14.34% | -24.43% | -39.03% | -4.56% | 8.19% | -0.86% |
Free Cash Flow Margin | -3.14% | -1.70% | -9.98% | -8.27% | -4.95% | -5.70% |
EBITDA | -8,747 | -7,280 | -21,363 | -2,623 | 6,199 | 3,123 |
EBITDA Margin | -5.89% | -5.64% | -22.36% | -2.15% | 6.20% | 4.27% |
D&A For EBITDA | 789.64 | 1,179 | 2,514 | 1,923 | 1,452 | 1,242 |
EBIT | -9,537 | -8,459 | -23,878 | -4,546 | 4,747 | 1,881 |
EBIT Margin | -6.42% | -6.55% | -24.99% | -3.72% | 4.75% | 2.57% |
Effective Tax Rate | - | - | - | - | 9.00% | 59.73% |
Advertising Expenses | - | 292.87 | 426.79 | 256.24 | 418.04 | 519.69 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.